Okay. Thank you.
I have another question. We talked about screening. When you're screening for a disease, if we have a group of people who came back from a certain area with a disease, you're screening for it. You look for, let's say, malaria, if they've been to a malaria.... I'm just using that as an example of what you might be screening for in a population. You have evidence to believe that the screening you're going to do is going to confirm the diagnosis. You do a blood test for malaria, and these sorts of things. Now, as to this request for screening for mefloquine toxicity, in the letter from Dr. Nevin, which I have here, the screening tool that he talks about—and I'm obviously condensing this: Do you have neuropsychiatric symptoms and did you take mefloquine—is there any science supporting the contention that this series of questions would in any way, shape or form support the diagnosis of mefloquine toxicity?